Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist

GlobeNewswire11-07

MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481904837?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/nFPIV6UEv5MtRZH7nCVaFQ--~B/aD0xNTg7dz0zMjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9fc709677795ec8aacefdbb92bf7c00b","is_english":true,"pubTime":"2024-11-07 21:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481904837","market":"us","top_or_hot":-1,"title":"Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist","media":"GlobeNewswire","content":"<div>\n<p>MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE: ANVS) (\"Annovis\" or the \"Company\"), a late-stage clinical drug platform company developing transformative therapies ...</p>\n\n<a href=\"https://finance.yahoo.com/news/annovis-bio-appoints-matthew-peterson-130000124.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnnovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/annovis-bio-appoints-matthew-peterson-130000124.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE: ANVS) (\"Annovis\" or the \"Company\"), a late-stage clinical drug platform company developing transformative therapies ...</p>\n\n<a href=\"https://finance.yahoo.com/news/annovis-bio-appoints-matthew-peterson-130000124.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0164881194.USD","symbol_name":"HSBC GIF INDIAN EQUITY \"AC\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/annovis-bio-appoints-matthew-peterson-130000124.html","article_id":"2481904837","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/nFPIV6UEv5MtRZH7nCVaFQ--~B/aD0xNTg7dz0zMjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9fc709677795ec8aacefdbb92bf7c00b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481904837","pubTimestamp":1730984400,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"MALVERN, Pa., Nov. 07, 2024  -- via IBN --Annovis Bio Inc.  , a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease  and Parkinson’s disease , today announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct, reporting, and successful completion of Annovis’ clinical trials.\"We are thrilled to welcome Matthew Peterson to our team,\" said Cheng Fang, Ph.D., Senior Vice President, Research and Development, at Annovis. \"Dr. Peterson brings an impressive track record in clinical research and a passion for improving patient outcomes, joining us at a crucial moment as we are approaching initiation of pivotal Phase 3 studies.”\"I am excited to join Annovis and to work alongside such a dedicated team at this pivotal moment for the company,\" said Dr. Peterson. \"I look forward","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0164881194.USD":"HSBC GIF INDIAN EQUITY \"AC\" (USD) ACC","LU0823038988.USD":"AMUNDI FUNDS ASIA EQUITY FOCUS  \"A2\" (USD) ACC","LU0531971678.HKD":"HSBC GIF INDIAN EQUITY \"AD\" (HKD) INC","LU0251143458.SGD":"Fidelity Emerging Markets A-SGD","LU0823039010.USD":"AMUNDI FUNDS ASIA EQUITY FOCUS  \"A2\" (USD) INC","BK4548":"巴美列捷福持仓","PD":"PagerDuty, Inc.","LU1102505762.USD":"富达新兴市场焦点 A","LU1868838027.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES \"8\" (USD) ACC","LU1102505929.USD":"FIDELITY SUSTAINABLE EMERGING MARKETS EQUITY  \"A\" (USD) ACC","BK4023":"应用软件","LU0143863784.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES\"DU\" (USD) ACC","LU0264410563.USD":"SCHRODER ISF INDIAN EQUITY \"A\" ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4523":"印度概念","BK4585":"ETF&股票定投概念","IE00B7N09G41.SGD":"柏瑞印度股票A5CP SGD","BK4139":"生物科技","LU1868837565.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES \"1\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU0143863198.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES\"AU\" (USD) ACC","BK4535":"淡马锡持仓","ANVS":"Annovis Bio, Inc.","IBN":"印度工业信贷投资银行","LU0066902890.USD":"HSBC GIF INDIAN EQUITY \"AD\" (USD) INC","BK4588":"碎股","IE00BYTNYM70.SGD":"PINEBRIDGE INDIA EQUITY \"A5\" (SGD) ACC","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU1868837722.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES \"2\" (USD) ACC","IE00B0JY6M65.USD":"PINEBRIDGE INDIA EQUITY \"A\" (USD) ACC","LU0828237940.HKD":"SCHRODER ISF EMERGING ASIA \"A\" (HKD) ACC","BK4207":"综合性银行"},"translate_title":"Annovis Bio任命Matthew Peterson博士为高级临床科学家","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PD":1,"ANVS":1,"IBN":1},"content_text":"MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE: ANVS) (\"Annovis\" or the \"Company\"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct, reporting, and successful completion of Annovis’ clinical trials.\n\"We are thrilled to welcome Matthew Peterson to our team,\" said Cheng Fang, Ph.D., Senior Vice President, Research and Development, at Annovis. \"Dr. Peterson brings an impressive track record in clinical research and a passion for improving patient outcomes, joining us at a crucial moment as we are approaching initiation of pivotal Phase 3 studies.”\nDr. Peterson joins Annovis with experience in both academic research and the life sciences industry. Most recently, he served as Senior Clinical Research Science Manager at Axogen, where he focused on therapies for peripheral nerve repair and regeneration. His previous roles include Clinical Research Scientist Contractor at Ethicon and Senior Clinical Project Manager at Exactech, along with a decade-long tenure at the Department of Veterans Affairs (VA). During his time at the VA, Dr. Peterson led studies on pressure ulcer prevention, fall risk assessment, and interventions to improve the quality of life for veterans with spinal cord injuries and other conditions. Dr. Peterson holds a Ph.D. in Biomedical Engineering from the University of Florida, where he specialized in developing technologies aimed at reducing clinical complications for vulnerable patient populations. He has authored numerous peer-reviewed publications and served as a principal investigator on studies funded by organizations including the Department of Defense and the VA.\n\"I am excited to join Annovis and to work alongside such a dedicated team at this pivotal moment for the company,\" said Dr. Peterson. \"I look forward to contributing to the clinical development of buntanetap and supporting the company’s goal of bringing transformative therapies to patients affected by neurodegenerative diseases.\"\nAbout Annovis Bio\nHeadquartered in Malvern, Pennsylvania, Annovis Bio is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.\nInvestor Alerts\nInterested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.annovisbio.com/email-alerts. Additionally, we invite you to explore our updated investor website, which provides comprehensive access to company news, financial reports, and other key information.\nForward-Looking Statements\nThis press release contains \"forward-looking\" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the \"Risk Factors\" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.\nContact Information: Annovis Bio Inc. 101 Lindenwood Drive Suite 225 Malvern, PA 19355 www.annovisbio.com\nInvestor Contact: Scott McGowan InvestorBrandNetwork (IBN) Phone: 310.299.1717 www.annovisbio.com/investors-relations IR@annovisbio.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481904837"}